Clonazepam Recall Expands; Lipid Depression Screening; Period Pain and Depression
The FDA broadcast Endo’s expanded recall of clonazepam tablets, used for panic disorder among other conditions, due to potential product carton strength mislabeling.
After controlling for immortal time bias, high-dose antipsychotic and benzodiazepine use was associated with increased mortality in a large study of people with schizophrenia. (JAMA Network Open)
Researchers suggested lipid-based biomarkers may be useful in screening for depression in the general population. (eBioMedicine)
Three-fourths of U.S. women and nearly two-thirds of men said they want their healthcare provider to ask them about mental health in addition to physical health concerns, according to a Gallup poll.
FDA researchers presented preliminary research on how the asthma drug montelukast (Singulair) affects the brain; the drug has carried a black box warning about neuropsychiatric effects since 2020. (Reuters)
U.K. Biobank data showed that irregular sleep was strongly associated with a higher risk of major adverse cardiovascular events. (Journal of Epidemiology and Community Health)
A Mendelian randomization study suggested a causal relationship between dysmenorrhea and depression. (Briefings in Bioinformatics)
Digital devices like smartwatches and fitness trackers may help predict episodes of mania and depression in people with bipolar disorder. (Acta Psychiatrica Scandinavica)
Could a “yoga pill” help ease anxiety symptoms? (Los Angeles Times)
In response to a New York City stabbing spree last week that left three people dead, Mayor Eric Adams renewed his push for state legislation that would clarify and expand criteria for individuals to be hospitalized for psychiatric care against their will. (Gothamist)
One psychiatrist detailed her own battle with severe mental illness. (The Guardian)
The Biden Administration released new resources to help communities address the trauma and mental health impacts of gun violence.
